Ben Zhao, Ph.D.

Ben Zhao, Ph.D.

President & Founder

Ph.D. in Pharmaceutical Science, Ohio State University

Engaged in the research of drug delivery technology for 20+ years

Former FDA Senior Reviewer, CMC Expert; responsible for the approval of complex drugs, including nucleic acids, peptides, liposomes and cGMP quality system

Meng Xiaofeng  Ph.D/MBA

Meng Xiaofeng Ph.D/MBA

Co-president

PhD /MBA from the State University of New Jersey, Master from Shanghai Institute of Pharmaceutical Industry

More than 20 years of senior experience in the pharmaceutical industry, international regulatory registration and GMP field of authoritative experts

Good at drug development management, international regulatory registration, quality system construction and global market development. He has led the listing of many new drugs and more than 100 generic drugs in Europe and the United States, and promoted Chinese OTC softgel drugs to enter the mainstream channel in the United States

Robert J. Lee, Ph.D.

Robert J. Lee, Ph.D.

Chief Scientist

Tenured Professor, Ohio State University

Expert in liposome/nanoparticle delivery system, targeted drug delivery system, non-viral gene delivery system, and small nucleic acid delivery system

Yang Yongsheng, Ph.D.

Yang Yongsheng, Ph.D.

Senior Vice President, Director of Nucleic Acid Medicine Innovation Center

Postdoctoral Fellow, University of Michigan

Engaged in the research on gene therapy and gene delivery system

Previously served as a senior pharmacologist at the US FDA, responsible for conducting research on biopharmaceutics and drug quality of new drugs and generic drugs, and review of bioequivalence of complex preparations and locally acting drugs

Angela Men, M.D., Ph.D.

Angela Men, M.D., Ph.D.

Chief Medical Officer

Ph.D. in Pharmaceutical Science, Virginia State University

Clinical Medicine of Tianjin Medical University/Resident Physician at the Second Hospital of Tianjin Medical University

Previously served as a Senior, Special Approving Officer and Head of the Drug Approval Team of the US FDA Center for Drug Approval

Zhang Mengzi, Ph.D.

Zhang Mengzi, Ph.D.

Head of Regulatory Affairs

With more than 10 years’ experience in R&D and regulatory affairs; developed global regulatory strategic solutions for pharmaceutical and biotech companies, focusing on the regulatory framework and market in the United States and China

Holly Yang

Holly Yang

Chief Financial Officer

Dual Master’s degrees in Enterprise Risk Management & Healthcare Management, Johns Hopkins University

Deutsche Bank, China Merchants Securities, Accenture, etc., with five years’ experience in corporate finance and financial affairs, focusing on accounting policies in China and the United States